Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin SinoBiotech Ltd.
• Collaborator: Beijing Cancer Hospital

Criteria

Inclusion Criteria:

• chemotherapy induced neutropenia

Exclusion Criteria:

• treated with other biological drugs or other neutropenia therapy drugs